Andrew L. Pecora, MD, CPE: I’m not an economist, but I’ve read somewhat about economic theory, and one of the things that economists do is they think a lot about incentives to change behavior. And I just wonder if, as you answer this, if you could also put your economist’s hat on and give us your view. Is it a proper incentive for doctors to have downside risk? And what do you see as the potential risk of doing that?
Rena M. Conti, PhD: Right. So, I do not believe that bundled payment or risk-based payment that has a downside component to it will ever fully take over all of oncology care for the following reasons. Bundled payment and episode-based payment essentially put physicians and physician practices in the driver’s seat, with very strong incentives to reduce cost as much as possible and, at the same time, provide standard of care. There is a real risk of stinting on care or shunning certain types of patients that don’t fit perfectly in standard treatments because they’re too sick, they have other things going on in terms of other diseases, or they have other types of social service needs that make them a bad risk from a bundled-payment perspective.
The other thing that concerns me, or is part of something that we need to worry a little bit about, is innovation. In areas where there is very significant innovation that’s kind of happening in a sequential wave—I would argue non—small cell lung cancer treatment is like that, some of the leukemias are like that, as well, right now—there is incentive in the bundled payment to not give patients those new, really expensive treatments because if you do, you’ll blow your bundle. And so, there’s kind of an incentive to either not provide that care or put off providing that care to another episode. I’m not sure that that’s the right way of thinking about providing care to patients, particularly in an area of medicine where we’re seeing so much scientific promise. But, also, all Americans should share in that scientific promise, not just the ones that look like they’re the right risk type.
Because of that, I think we’ll see bundled or episode-based payments come in in areas of cancer where there’s a set of treatments that can be chosen from among where you can define the cancer really well and where we can kind of match treatments to those patient types pretty easily. But, in areas where there’s a significant amount of innovation, we may see pathway-type development to reduce that incentive to stint on care or not provide innovative care to patients.
Andrew L. Pecora, MD, CPE: Just a quick anecdote. So, when we went and proposed bundles, we had to present it to the Department of Banking and Insurance and we had to address all of the issues you just raised. Now, we were able to address them successfully because of the quality of data we have. And, in fact, you can have carve-outs in a bundle that allow for innovation and comorbidities.
Rena M. Conti, PhD: Right. So, carve-outs are another way of trying to deal with reducing the incentive to stint.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More